“…This abberant brain and neurotransmission condition leads to Alzheimer's disease (AD) pathogenesis (Li et al, 2015;Willcox, Scapagnini, & Willcox, 2014) that contributes to increased global morbidity/mortality rate (US Burden of Disease Collaborators, 2013). The high catalytic efficiency (CE) of AChE and the importance of its inhibition in AD management has been an important research focus in the development of various therapeutic agents (Acharya, Dutta, Chaudhury, & De, 2018;Li et al, 2015;Olarewaju et al, 2018;Saravanaraman, Chinnadurai, & Boopathy, 2014;Taslimi & Gulçin, 2018;Yadav & Appukuttan, 2019;Yatesa et al, 2019;Zare-Zardini, Tolueinia, Hashemi, Ebrahimi, & Fesahat, 2013). Several synthetic AChE-inhibitory drugs have been developed for use against neurodegenerative diseases, such as dementia and AD; however, these drugs are associated with severe negative side effects (Ghribia, Ghouilaa, Omrib, Besbesb, & Janneta, 2014;Iannello et al, 2014;Kumar & Chowdhury, 2014).…”